Table 1.
Prevalence of endocrine-related immune-related adverse events in subjects with various types of cancer.
| Non-small cell lung cancer (n=158) |
Gastrointestinal cancer (n=103) |
Hepatocellular carcinoma (n=37) |
Otorhinolaryngo-logical cancer (n=35) |
Urinary tract cancer (n=34) |
Malignant melanoma (n=31) |
Renal cell carcinoma (n=28) |
|
|---|---|---|---|---|---|---|---|
| Presence of endocrine-related irAEs (%) | 22.8 | 17.5 | 46.0 | 6.7 | 17.7 | 35.5 | 53.6 |
| Mortality within 12 months of ICI administration (%) | 39.3 | 34.6 | 18.8 | 21.2 | 31.3 | 16.1 | 20.0 |
| Mean time to death (days) | 328.1±82.1 | 202.2±109.0 | 208.7±257.0 | 82.4±238.0 | 192.4±199.9 | 360.0±281.5 | 281.5 |
| Immune checkpoint inhibitors administered | |||||||
| Ipilimumab (%) | 3.2 | 0 | 0 | 2.9 | 2.9 | 29.0 | 28.6 |
| Nivolumab (%) | 24.7 | 90.3 | 0 | 60.0 | 0 | 35.5 | 35.7 |
| Pembrolizumab (%) | 50.6 | 9.7 | 0 | 37.1 | 91.2 | 35.5 | 28.6 |
| Atezolizumab (%) | 13.3 | 0 | 100.0 | 0 | 0 | 0 | 0 |
| Dulbumumab (%) | 8.2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Avelumab (%) | 0 | 0 | 0 | 0 | 5.9 | 0 | 7.1 |
| Small cell lung carcinoma (n=12) |
Hematologic tumor (n=8) |
Cancer of unknown primary (n=8) |
Malignant pleural mesothelioma (n=4) |
Cancer of female genital organs (n=4) |
Breast cancer (n=3) |
Pancreatic cancer (n=1) |
|
| Presence of endocrine-related irAEs (%) | 16.7 | 12.5 | 12.5 | 50.0 | 25.0 | 0 | 100 |
| Mortality within 12 months of ICI administration (%) | 54.6 | 12.5 | 57.1 | 66.7 | 33.3 | 66.7 | 0 |
| Mean time to death (days) | 240.8±257.0 | 240.0 | 101.0±314.8 | 185.5±355.1 | 40 | 132.5±445.1 | – |
| Immune checkpoint inhibitors administered | |||||||
| Ipilimumab (%) | 0 | 0 | 0 | 25.0 | 0 | 0 | 0 |
| Nivolumab (%) | 0 | 50.0 | 62.5 | 75.0 | 50.0 | 0 | 100 |
| Pembrolizumab (%) | 0 | 50.0 | 37.5 | 0 | 50.0 | 0 | 0 |
| Atezolizumab (%) | 100 | 0 | 0 | 0 | 0 | 100 | 0 |
| Dulbumumab (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Avelumab (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Data are expressed as mean and standard deviation. irAE, immune-related adverse events; ICI, immune checkpoint inhibitor.